91 results about "Amphetamine use" patented technology

Disclosed are pharmaceutical compositions and formulations of enantiomerically enriched or pure 3,4-methylenedioxymethamphetamine (MDMA) and methods for modulating aggression response behaviors that may be associated with a disorder and / or disease.

The invention can provide compounds, analogs of blebbistatin, effective and selective inhibitors of nonmuscle myosin II relative to cardiac myosin II. Compounds can be used in the method of treating a disease, disorder, or medical condition in a patient, comprising modulating myosin II ATPase, such as treatment of substance abuse relapse disorder, or of renal disease, cancer and metastasis, benign prostate hyperplasia, hemostasis or thrombosis, nerve injury including retinal damage, lung fibrosis, liver fibrosis, arthrofibrosis, wound healing, spinal cord injury, periodontitis, glaucoma and immune-related diseases including multiple sclerosis; or wherein the disease, disorder, or medical condition comprises addiction including abuse of or addiction to anything classified as a Substance-Related or Addictive Disorder in the Diagnostic and Statistical Manual of Mental Disorders (DSM), such as, but not limited to, cocaine, opioids, amphetamines, ethanol, cannabis / marijuana, nicotine, and activities including gambling.Compounds are of general formulawith substituents as defined herein.

An oral amphetamine extended release solid dose is described. The compositions contain a combination of an uncoated amphetamine-cation exchange resin complex, a barrier coated amphetamine-cation exchange resin complex-matrix, and an uncomplexed amphetamine, wherein one or more of these components contains blends of different forms of amphetamines. Either the modified release coated and / or the uncoated amphetamine-cation exchange resin complex may have two forms of amphetamine in a complex with a single cation exchange resin. Following administration of a single dose of the composition, a therapeutically effective amount of amphetamine is reached by about one hour and the composition provides at least a thirteen hour effect post-dose.

The invention relates to the technical field of amphetamine drug detection, and particularly discloses a functional composite material, an expiration collection device assembled based on the functional composite material, a detection method and application. Wherein the functional composite material is formed by superposing and combining functional polypropylene cotton and a functional polypropylene film, the functional polypropylene cotton is obtained by modifying a polypropylene material with polydopamine and tetraethoxysilane, and the functional composite material can be assembled into the portable expiration collection device and is used for expiration collection. The invention also provides a detection method which comprises the following steps: enriching amphetamine drugs in exhaled air under the adsorption action of the functionalized composite material, then eluting the functionalized composite material, concentrating, carrying out constant volume filtration, and finally carrying out detection analysis by using high performance liquid chromatography-tandem triple quadrupole mass spectrometry. The method can be used for accurately and quickly screening the drug addicts, and is also suitable for screening the drug addicts with low drug intake and low drug concentration in expiration to pg level after long-time metabolism.

The present invention relates to novel hydroxynorketamine (HNK) analogs, and uses thereof in the treatment of pain, inflammation and neurodegenerative diseases.

The invention discloses application of lycium barbarum polysaccharide in preparation of a medicine for inhibiting methylamphetamine-induced nerve injury, and relates to the technical field of biological medicines. It is found and proved that lycium barbarum polysaccharide can inhibit methylamphetamine-induced nerve injury, and the effect is remarkable. From the aspect of cell survival, the survival rate of the microglial cells pretreated by the lycium barbarum polysaccharide after METH stimulation is obviously improved. In the molecular mechanism, the lycium barbarum polysaccharide can effectively lower the protein expression level of the METH-induced pyroptosis marker, the content of inflammatory factors IL-1beta and IL-18 can be reduced, and the release of lactic dehydrogenase is reduced. The result shows that the lycium barbarum polysaccharide can alleviate inflammatory response by inhibiting NLRP3 / ASC pathway mediated microglial cell pyroptosis, thereby inhibiting METH-induced nerve injury. The invention provides a new direction for developing METH neurotoxicity intervention medicines.

The present disclosure relates to 3,4-methylenedioxymethamphetamine (MDMA) or a pharmaceutically acceptable salt and / or solvate thereof, pharmaceutical compositions and dosage forms containing these particles, and methods of using pharmaceutical compositions and dosage forms containing these particles to treat subjects suffering from disorders of the central nervous system.

The invention belongs to the technical field of medicines, and particularly relates to a preparation containing lisdexamphetamine dimesylate and a preparation method of the preparation. The preparation disclosed by the invention is prepared from the following raw materials in percentage: 10.0%-40.0% of lisdexamphetamine dimesylate, 56.2%-87.7% of microcrystalline cellulose, 2.0%-3.0% of croscarmellose sodium and 0.3%-0.8% of magnesium stearate. Wherein the water content of the microcrystalline cellulose is less than or equal to 4.0%. Compared with the existing preparation, the preparation disclosed by the invention is better in stability, the dissolution performance is consistent with that of the existing preparation, the quality and the use safety of the lisdexamphetamine dimesylate medicine can be effectively improved, and the preparation has a very good application prospect.

The present invention is directed to novel chemical compositions of matter, and in particular novel MDMA class of compounds having substituted methylenedioxyphenethylamine and substituted amphetamine, having a metabolically labile thioether group.

Described are methods for reducing the formation of amphetamine carbamate and amphetacarbamate in transdermal amphetamine compositions, compositions with low levels of amphetacarbamate, and methods using such compositions for transdermal delivery of amphetamine.

The application belongs to the technical field of water treatment, and particularly relates to a new psychoactive substance adsorbent and application thereof. The preparation method of the adsorbent comprises the following steps: (1) mixing and reacting activated shrimp shell biomass and ferroferric oxide nano magnetic material, drying, and pyrolyzing to obtain Fe3O4@BC; (2) mixing and reacting Fe3O4@BC and ZIF-8 to obtain Fe3O4@BC@ZIF-8; and (3) mixing and reacting a eutectic solvent with Fe3O4@BC@ZIF-8 to obtain the new psychoactive substance adsorbent. The adsorbent has strong adsorption capacity for 4-methyl methcathinone, methcathinone, amphetamine, methamphetamine and ephedrine, and the adsorption efficiency can reach 98% for 4-methyl methcathinone in particular.

The invention relates to a polymeric nanomaterial that has specific affinity for MeA (methamphetamine) or AMP (amphetamine-derived synthetic drugs) and can exist at the nanoscale, as well as to the synthesis method thereof.

The present application relates to a kind of drug rapid detection method, equipment and medium based on photonic crystal image, comprising: image pre-processing, to locate the position of photonic crystal in image and cut image, so that only photonic crystal is left in the image after cutting;Extract the color feature vector of the photonic crystal, and carry out dimension reduction processing;The color feature vector after dimension reduction is converted, identified and compared based on support vector machine, and the drug identification of the to-be-measured body fluid is completed.The present application is based on the color difference of different drugs and photonic crystal after reaction, judges what kind of drug, such as amphetamine, pseudoephedrine, chloroephedrine, methylcathinone or methamphetamine, contained in the to-be-measured liquid by comparing with standard spectrum, fast, low cost, mass detection, low equipment cost.

The invention relates to a medicine with drug rehabilitation and relapse prevention effects as well as a preparation method and application thereof, and belongs to the field of medicines. The medicine comprises rotundine and salts and is prepared through a chemical synthesis method, and experiments prove that the medicine preparation has the effects of treating opioid substances including heroin, morphine, dolantin, methadone and the like as well as other psychoactive substances, such as opioid and the like. Independent or addiction formed by cocaine, amphetamine stimulants, wine, smoke, cannabis sativa, sedative and hypnotic drugs and the like has the effects of detoxifying, relieving symptoms, inhibiting psychological craving and reducing relapse rate.

The invention discloses a method for preparing (S)-(-)-1-amphetamine. According to the method, propiophenone serves as a substrate and is converted into (S)-(-)-1-amphetamine under the catalytic action of imine reductase and ammonia water, the conversion rate is larger than or equal to 99%, and the ee value of the product is larger than or equal to 99%. The method disclosed by the invention is simple to operate and high in atom economy, and can be used for industrial production.

A process for producing a nitrogen-doped peony-shaped molybdenum oxide, comprising the following steps: (1) adding a regulator to a molybdenum-containing solution for reacting, concentrating and thermally treating to obtain a peony-shaped molybdenum oxide; and (2) dissolving the peony-shaped molybdenum oxide in a conditioning agent and adding an amine source for standing, centrifuging, washing, and heat-treating, thereby obtaining the nitrogen-doped peony-shaped molybdenum oxide; wherein the regulator is at least one of the following: nitric acid, ammonium nitrate, sodium persulfate, ammonium persulfate, concentrated sulfuric acid, H2O2, ozone, sodium hypochlorite, wherein in step (2), the conditioning agent is at least one of the following: sodium acetate, ammonium acetate, sodium formate, diaminoethane, sodium oxalate, ammonium benzoate, sodium phenylacetate, sodium propionate, sodium tartrate, sodium citrate, ammonium citrate; and wherein in step (2) the amine source is at least one of the following: aniline, dimethylamine, trimethylamine, benzylamine, phenethylamine, ethylamine, diethylamine, propylamine, phenylenediamine, xylylenediamine, amphetamine.

The invention provides a method for colorimetrically detecting amphetamine and methyamphetamine in drugs based on furyl probes. The furyl probes in the method are furan-indanone, furan-indene dicyanide and furan-indene cyanide respectively. Wherein before and after amphetamine or methyl amphetamine is added into the probe furan-indanone, the color of the solution is changed from faint yellow to rose red; before and after amphetamine or methyl amphetamine is added into the probe furan-indene dicyanide, the color of the solution is changed from brown yellow to blue; the color of the solution is changed from yellow to orange before and after amphetamine is added into the probe furan-indene cyanogen, and the color of the solution is changed from yellow to green before and after methylamphetamine is added into the probe furan-indene cyanogen. Rapid colorimetric distinguishing of single amphetamine or methyamphetamine and qualitative detection of a mixture of amphetamine and methyamphetamine are achieved. The method has no special limitation in use, can quickly complete qualitative detection without pretreatment of an object to be detected, is simple to operate, economical, practical, high in specificity and sensitivity, stable and repeatable in result, and can be practically applied and popularized.

The application provides a compound composition for preventing and treating motion sickness and a preparation method thereof, the compound composition comprises the following raw materials in parts by weight: dimenhydrinate 2-6 parts, dextroamphetamine 0.2-0.6 parts, ginger 20-50 parts, dried tangerine or orange peel 10-20 parts, privet fruit 8-15 parts, tribulus terrestris 8-15 parts, rhizoma alocasia 5-12 parts, pachystachys jamaicensis 8-15 parts, daya flower 5-10 parts, litsea cubeba 3-8 parts, kaempferia 3-8 parts, ipomoea alba 5-10 parts, menthol 0.5-3 parts; the compound composition of the application realizes the enhancement of the anti-motion effect and the offset of the side effects, and especially significantly reduces the drowsiness caused by dimenhydrinate and the potential risk of excessive nerve excitement of dextroamphetamine.

This invention provides a method for constructing a donor-acceptor type perylene diimide-based porous conjugated polymer probe and detecting methamphetamine and amphetamine solutions. The method synthesizes donor-acceptor type perylene diimide-based porous conjugated polymer probes with different topologies by combining an electron acceptor perylene diimide derivative and an electron donor aggregation-induced emission fluorophore via a succinate coupling reaction. When used for the detection of methamphetamine and amphetamine, this system exhibits a clear ratiometric fluorescence response, with the fluorescence color gradually changing from yellow-green to orange and orange-red, demonstrating a significant ratiometric fluorescence response. It features fast response speed, high detection sensitivity, good selectivity, and no interference from other common structurally and property-similar substances, enabling the differentiation and identification of methamphetamine and amphetamine.

There is disclosed an improved abuse-deterrent pharmaceutical composition comprising a controlled pharmaceutical substance in a formulation comprising at least two gel-forming excipients selected from the group consisting of PEG ester, poloxamer, water-soluble anionic polysaccharide, and carboxymethylcellulose, and a bitter-agonist compound selected from the group consisting of denatonium salts (including denatonium acetate (DA), denatonium benzoate (DB), denatonium chloride, denatonium citrate, denatonium maleate, denatonium saccharide, and denatonium tartrate) chlorpheniramine, diphenidol, famotidine, haloperidol, quinine, parthenolide, and aristolochic acid. Preferably, the controlled pharmaceutical substance is an amphetamine or a pharmaceutically acceptable salt thereof. Preferably, the bitter receptor agonist is a denatonium salt selected from DA, DB, denatonium chloride, denatonium citrate, denatonium maleate, denatonium saccharide, and denatonium tartrate provided at from about 0.5 mg per dose administered to about 10 mg per dose administered. There is further disclosed a use for denatonium acetate (DA) as a pharmaceutical grade aversive agent to be added to abuse-deterrent formulations to deter snorting or smoking a controlled pharmaceutical substance at a dose of about 0.5 mg to about 10 mg per dose.

An efficient, economical and continuous process for the preparation of L-lysine-D-amphetamine dimesylate is provided.

The present invention belongs to the field of biomedicine, and discloses the application of eleutheroside B in the preparation of drugs for preventing and / or treating methamphetamine addiction withdrawal. The inventor evaluated the role of eleutheroside B in preventing and treating methamphetamine addiction by investigating the effects of eleutheroside B on methamphetamine-induced conditioned place preference and behavioral sensitization. It was experimentally confirmed that eleutheroside B could reverse methamphetamine-induced conditioned place preference and reduce methamphetamine-induced hyperlocomotor activity, and had an inhibitory effect on the expression of methamphetamine-induced behavioral sensitization in mice, indicating that eleutheroside B could effectively weaken the dependence and craving for methamphetamine, weaken the induced behavioral sensitization effect, and could be used for preventing and treating methamphetamine addiction. The present invention develops a new drug for drug rehabilitation with eleutheroside B as the active ingredient, provides an effective and safe option for the prevention and treatment of methamphetamine addiction, and has good clinical application prospects.

The invention relates to the technical field of drug analysis, in particular to a chiral derivatization detection method for methylamphetamine and amphetamine enantiomers, which at least comprises the following steps: (1) adding an internal standard solution, a buffer solution and a derivatization reagent into a sample to be detected for derivatization reaction; (2) after the derivatization reaction, adding an extracting agent for liquid-liquid extraction, blow-drying an organic phase after liquid-liquid extraction, and redissolving with a redissolving solvent to obtain a redissolving solution; and (3) carrying out liquid chromatography-high resolution mass spectrometry detection on the redissolved solution, and carrying out qualitative and semi-quantitative determination according to the detection result, the method is used for detecting enantiomers of methamphetamine and amphetamine in a complex biological sample, and the method has the advantages of good separation degree, good repeatability, high sensitivity and high detection sensitivity, and can be used for detecting the enantiomers of methamphetamine and amphetamine in the complex biological sample. The method has good practicability in the aspects of judicial expertise and stimulant screening.

Described herein are neurotrophic and nootropic compositions and methods for treating subjects with such compositions. In one aspect the composition comprises one or more tryptamines or in pure form or extracts from psilocybin containing mushrooms, or combinations thereof optionally combined with one or more phenethylamines or amphetamines in pure form or extracts from a plant or mushroom, or combinations thereof, optionally one or more erinacines or hericenones in pure form, extracts from Hericium mushroom species (e.g., H. erinaceus, H. coralloides, H. ramosum) or combinations thereof, optionally one or more cannabinoids in pure form or extracts from Cannabis sativa, Cannabis sativa, Cannabis indica, or Cannabis ruderalis, optionally, one or more adversive compounds, and optionally one or more pharmaceutically acceptable excipients.

Described herein are methods for quantitatively determining the amount of the amphetamine-related compound identified herein as amphetamine carbamate (amphetammonium-amphetacarbamate) present in a drug-containing polymer matrix comprising amphetamine, and for assessing a drug-containing polymer matrix comprising amphetamine. The methods may comprise converting any amphetacarbamate present into reaction products comprising carbonate, quantifying the amount of carbonate, and quantifying the amphetacarbamate originally present from the quantified amount of carbonate.